These data suggest that blockade of IL-18 at the time of administering E7 DNA vaccine plus α-GalCer and MPL combination decreases the vaccine-driven antitumor response against TC-1 tumor as compared with other treatments. The gene discussed is IL18; the disease is neoplasm.